Abstract
The identification of mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC). The effectiveness of individualized treatment using EGFR tyrosine kinase inhibitors (TKIs) for EGFRmutated NSCLC has mainly been clarified in clinical trials within Japan, and EGFR-TKI monotherapy has been established as the standard first-line treatment for EGFR-mutated NSCLC. Since then, combination regimens involving EGFR-TKI and chemotherapy or anti-angiogenic agents have been developed. Regarding combinations, the NEJ009 study conducted in Japan showed a significant prolongation of progression-free survival and overall survival compared with gefitinib alone. The NEJ009 regimen may be a reasonable option for patients with good performance status in terms of risk-benefit balance. However, further investigation is warranted to improve clinical outcomes in EGFR-mutated NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 266-272 |
| Number of pages | 7 |
| Journal | Proceedings of the Japan Academy Series B: Physical and Biological Sciences |
| Volume | 96 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2020 |
Keywords
- Chemotherapy
- EGFR mutation
- EGFR-TKI
- Lung cancer
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Physics and Astronomy(all)
